NICE okays regular NHS funding for Novartis' breast cancer d...

NICE has recommended moving Novartis’ Kisqali (ribociclib) from interim funding arrangements to regular NHS reimbursement for certain previously treated breast cancer patients.

Revamped Novartis highlights top R&D programmes at managemen...

With a reorganisation of Novartis now nearing completion, the Swiss pharma group is laying out its plans for growth at a meeting with investors and analysts, which it says will be driven ma

Novartis CEO thinks 2nd health lockdown unlikely, as Q3 sale...

Novartis’ pharmaceutical sales recovered in the third quarter of this year after an earlier COVID-19 decline, as new drugs like gene therapy Zolgensma gathered pace.  

NICE changes its mind on Novartis’ Kisqali for breast cancer